Synergistic antibiotic activity against planktonic and biofilm-embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis

Objectives To determine the antimicrobial activity against streptococcal biofilm in species mostly isolated from implant-associated infections and examine the effect of enzyme treatment of biofilm on the antimicrobial activity of different antibiotics. Methods The activities of fosfomycin, rifampicin, benzylpenicillin, daptomycin, gentamicin, levofloxacin, proteinase K and their combinations on planktonic and/or biofilm-embedded standard laboratory strains of Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis were investigated in vitro by standard methods and isothermal microcalorimetry. Results MIC values obtained for the tested antimicrobials against planktonic bacteria ranged from 0.016 to 128 mg/L for the three species tested. Higher antibiotic concentrations were usually required to reduce biofilm in comparison with planktonic bacteria, with the exception of gentamicin, for which similar concentrations (4-16 mg/L) exerted an effect on both planktonic and biofilm cells. A synergistic effect against the streptococcal biofilm of the three species was observed when gentamicin was combined with benzylpenicillin or with rifampicin. Moreover, antibiotic concentrations comparable to the MIC observed against planktonic cells induced a strong reduction of viable bacteria in proteinase K pre-treated biofilm. Conclusions This study shows that the combination of gentamicin with either benzylpenicillin or rifampicin exerts a synergistic effect against biofilms produced by the tested streptococci strains in vitro. Our results also suggest that coupling a dispersal agent with conventional antibiotics may facilitate their access to the bacteria within the biofilm. In vivo and clinical studies are needed in order to confirm whether such a strategy may be effective in the treatment of implant-associated infections caused by streptococci.

[1]  C. Perka,et al.  High failure rates in treatment of streptococcal periprosthetic joint infection: RESULTS FROM A SEVEN‐YEAR RETROSPECTIVE COHORT STUDY , 2017, The bone & joint journal.

[2]  P. Sendi,et al.  In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus , 2017, Journal of Antimicrobial Chemotherapy.

[3]  C. Hulet,et al.  Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations , 2016, BMC Infectious Diseases.

[4]  A. Trampuz,et al.  Activities of Fosfomycin and Rifampin on Planktonic and Adherent Enterococcus faecalis Strains in an Experimental Foreign-Body Infection Model , 2013, Antimicrobial Agents and Chemotherapy.

[5]  B. Henriques-Normark,et al.  Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  P. Choong,et al.  Management of Prosthetic Infection According to Organism , 2013 .

[7]  S. Shukla,et al.  Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K , 2012, The Journal of Antibiotics.

[8]  S. Cardona,et al.  Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci , 2011, The Journal of Antibiotics.

[9]  K. Boggian,et al.  Group B streptococcus in prosthetic hip and knee joint-associated infections. , 2011, The Journal of hospital infection.

[10]  James J. Collins,et al.  Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides , 2011, Nature.

[11]  C. Malone,et al.  Biofilm dispersal of community‐associated methicillin‐resistant Staphylococcus aureus on orthopedic implant material , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  M. Lavigne,et al.  Group B streptococcal prosthetic joint infections: a retrospective study of 30 cases. , 2009, Presse medicale.

[13]  M. Falagas,et al.  Susceptibility of Urinary Tract Bacteria to Fosfomycin , 2009, Antimicrobial Agents and Chemotherapy.

[14]  D. Wirz,et al.  Isothermal micro calorimetry – a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus , 2009, BMC Microbiology.

[15]  J. Greenleaf,et al.  Sonication of removed hip and knee prostheses for diagnosis of infection. , 2007, The New England journal of medicine.

[16]  Á. Pascual,et al.  In Vitro Activity of Fosfomycin against Extended-Spectrum-β-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Comparison of Susceptibility Testing Procedures , 2006, Antimicrobial Agents and Chemotherapy.

[17]  W. Zimmerli,et al.  Prosthetic joint infections: update in diagnosis and treatment. , 2005, Swiss medical weekly.

[18]  Ronald N. Jones,et al.  Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. , 2005, The Journal of antimicrobial chemotherapy.

[19]  W. Zimmerli,et al.  Prosthetic-joint infections. , 2004, The New England journal of medicine.

[20]  D. Murdoch,et al.  Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints , 2004, ANZ journal of surgery.

[21]  H. Kennedy,et al.  Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents , 2004, Scandinavian journal of infectious diseases.

[22]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[23]  A. Widmer New developments in diagnosis and treatment of infection in orthopedic implants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Farley Group B streptococcal disease in nonpregnant adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  W. Traub,et al.  Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. , 1997, Chemotherapy.

[26]  F. Lowy,et al.  Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci , 1986, Antimicrobial Agents and Chemotherapy.

[27]  D. Goldmann,et al.  In vitro activity of penicillin and rifampin against group B streptococci. , 1983, Reviews of infectious diseases.

[28]  F. Lowy,et al.  Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci , 1983, Antimicrobial Agents and Chemotherapy.

[29]  C. Norden Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. , 1975, The Journal of infectious diseases.

[30]  R. Moellering,et al.  Synergy of penicillin and gentamicin against Enterococci. , 1971, The Journal of infectious diseases.

[31]  M. Di Luca,et al.  Detection of Biofilms in Biopsies from Chronic Rhinosinusitis Patients: In Vitro Biofilm Forming Ability and Antimicrobial Susceptibility Testing in Biofilm Mode of Growth of Isolated Bacteria. , 2018, Advances in Experimental Medicine and Biology.

[32]  C. Doern,et al.  Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB). , 2009, Microbiology.

[33]  D. Vinh,et al.  Device-related infections: a review. , 2005, Journal of long-term effects of medical implants.